(75%). A deeper intronic mutation (c.1154-14G>A), identified in three unrelated patients with traces of disulphide dimers of antithrombin in plasma, created a cryptic splicing site that might generate a variant with 4 additional in frame residues according to in silico predictions. This aberrant splicing was confirmed by proteomic analysis of the dimer purified from plasma.
Conclusions:
A high proportion of cases with antithrombin deficiency (up to 13%) may be explained by an aberrant splicing. Up to 15% of mutations in SERPINC1: splicing site variations, gross gene defects and deep intronic mutations, may affect a correct splicing with three potential consequences type I, type II, and even moderate antithrombin deficiency.
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Essentials
• Increasing evidence supports a role for splicing defects in multiple disorders.
• For antithrombin (AT) deficiency only 7% of mutations disturb intronic splicing sequences.
• Our study of 141 unrelated cases with AT deficiency found higher rate of splicing defects (>13%).
• A wide range of gene defects cause different types of AT deficiency through aberrant splicing.
| INTRODUCTION
Antithrombin is a serpin (serin-protease inhibitor) considered as the main endogenous anticoagulant in humans. It exerts its anticoagulant function by inhibiting crucial serine proteases of the clotting cascade, mainly thrombin and factor Xa. 1 Thus, inherited antithrombin deficiency significantly increases the risk of thrombosis (20-to 40-fold).
Congenital antithrombin deficiency is a heterogeneous disorder that
shows an autosomal dominant pattern of inheritance. Deficiency is estimated to have a prevalence of about 0.02% in the general population, while accounting for 1% of cases with confirmed deep vein thrombosis. 2 Two deficiency states are described: type I deficiency characterized by a parallel reduction in both functional and antigenic levels of antithrombin in plasma; and type II deficiency distinguished by the production and secretion of a variant protein to the plasma circulation with null or impaired inhibitor activity. 3 The gene encoding antithrombin, SERPINC1, is located on the long arm of chromosome 1 (q23-25), and comprises 7 exons and 6 introns spanning 13 574 bp of genomic DNA (ENSG00000117601). Noncoding regions consist of 11 980 bp (88% from the whole gene). 4, 5 Up to 80% of cases with suspicion of inherited antithrombin deficiency are caused by SERPINC1 gene defects 6 , although other gene defects may also cause antithrombin deficiency. 7 According to the Human Gene Mutation Database (HGMD), missense or nonsense mutations constitute more than 50% to the genetic defects identified in SERPINC1, followed by small deletions (19%), gross deletions, and small insertions (8.5% and 8.1%, respectively). Only 22 mutations affecting introns that might theoretically disrupt the natural mRNA processing have been described (7% of mutations identified in SERPINC1), all associated with type I deficiency. As different evidences are supporting the increased role of splicing defects on different human genetic diseases 8, 9 , the aim of this study was to identify new SERPINC1 genetic variations underlying antithrombin deficiency through an incorrect splicing in one of the largest cohorts of unrelated patients with this strong thrombophilia.
| MATERIALS AND METHODS

| Patients
During the last 20 years, our center recruited 141 unrelated Caucasian cases from different hospitals with suspicion of antithrombin deficiency (plasma anti-FXa activity <80% of a reference plasma generated with 100 healthy blood donors) presenting 89 different SERPINC1 gene defects.
The study was approved by the Ethics Committees of the Hospital General Universitario Reina Sofia in Murcia, Spain. All patients or their relatives, and controls (blood donors for the reference plasma) provided written informed consent. The normal range of antithrombin measurements (anti-FXa and antigen levels) was 80-120% with coefficient of variation of 5-7%.
| Blood collection
| Western blot analysis
Plasma antithrombin was evaluated by Western blot using different electrophoretic conditions described elsewhere. 11 The blotting was performed by using rabbit anti-human antithrombin polyclonal antibody (A9522, Sigma-Aldrich) followed by donkey anti-rabbit 
| Protein purification
Antithrombin disulphide-linked dimers from plasma of patients with c.1154-14G>A or the c.334C>T mutations were purified as described before. 12 Briefly, citrated plasma of patients were subjected to heparin affinity chromatography on HiTrap Heparin columns (GE Healthcare), 
| LC−ESI−MS/MS analysis
Microcapillary reverse-phase LC was performed with a nanoAcquity system (Waters, Saint-Quentin, France). Reversed phase separation of trypsin digests was performed with an Atlantis, C18, 3 μm, there were no restrictions on molecular weight and isoelectric point; the fixed modification was carbamidomethylation of cysteine; the variable modification was oxidation of methionine.
| Genetic analysis
The exons and flanking regions, as well as 1500 bp of the promoter region of SERPINC1, were sequenced in all patients with antithrombin deficiency. 13 Gross deletions were analyzed by multiplex ligationdependent probe amplification (MLPA) using the SALSAMLPA Kit P227 SerpinC1 (MRC Holland, Amsterdam, The Netherlands). 
| In silico analysis of potential splicing signals
| RESULTS
| Classical splicing mutations
Ten patients with severe thrombotic events (P1-P10) and type I antithrombin deficiency (mean of 48% anti-FXa activity and 51% of antigen levels) had 9 different heterozygous splice site mutations (Table 1) . Remarkably, P2 (with c.1218 +1G>A mutation) had lower antigen and anti-FXa activity than expected (Table 1) , which may be explained by additional modulating factors. Five of these splicing site mutations were not previously described in available mutation databases ( Table 1 ). All these mutations severely disturbed natural acceptor (N=7) or donor splicing sites (N=2). Three of them potentially affected the splicing of exon 6, two affecting exons 2 and 5, and single ones affecting the splicing of exons 1 and 3 (Table 1 ). It is remarkable that no mutation affecting the splicing of exon 4 has been described either in our cohort or in the HGMD. (Table 1 ). According to HSF in silico predictions, this deletion disrupted the exon 7 wild type acceptor splicing site (from 90% to 61% of splicing probability).
| Other variants
P12 and P13 (26-and 42-year-old patients with early deep venous thrombosis) presented gross gene rearrangements.
MLPA analysis of P12 revealed a profile suggesting a possible heterozygous deletion involving exon 4. Exon 4 must be absent from affected transcripts in P12. Accordingly, the processing of introns of the mutant transcript would be different from that followed by the wild type transcript, with altered reading frame resulting in a premature stop codon ( Figure 2 ). This mechanism likely explains the type I antithrombin deficiency identified in P12 (Table 1 and Figure 1 ).
F I G U R E 1 Plasma antithrombin in P11, P12, and P13 patients detected by Western Blot after electrophoretic separation in native-PAGE. A healthy blood donor was used as a negative control. AntiFXa activity and antigen levels are also indicated for each case. (Table 1) . Surprisingly, P13 with duplication of exon 6, had a moderate type I deficiency of antithrombin with anti-FXa and antigen levels of around 75% (Table 1 and Figure 1 ). The 193 bp duplication involving exon 6 may generate different potential alternative splicing, two of them able to render normal mRNA processing of SERPINC1, which may explain the moderate antithrombin deficiency detected in this patient (Figure 2 ). b (5) b (6) b (7) y (8) y (9) y (10) y (11) y (13) y ( 
| Deep intronic mutations
Although the design of primers used in this study does not allow detecting very deep intronic mutations, we identified one intronic variation not directly disturbing donor or acceptor sequences, c.1154-14G>A, that might cause antithrombin deficiency. This mutation was detected in three unrelated patients from Portugal and two different regions of Spain: P14, P15 and P16 (Table 1) . This mutation was previously described in a Dutch patient with type I antithrombin deficiency, and authors suggested this mutation to cause a splicing defect (CS941423). 15 Patients with this mutation from our cohort also showed an apparent type I deficiency, with a mean of around 50% of functional activity and antigen levels (Table 1) . However, and in agreement with a previous report 16 our patients with this mutation presented traces of disulphidelinked dimers in plasma, which had slightly slower electrophoretic mobility than those identified in patients with conformational missense mutations (c.334C>T; p.Pro112Ser) 11 ( Figure 3) .
In silico prediction suggested that c.1154-14G>A creates a new cryptic acceptor sequence, which may potentially generate a variant protein with the in-frame insertion of 4 residues at position 384 ( Figure 3) . Purification of disulphide-linked dimers from plasma of patients with this mutation and further proteomic analysis confirmed the predicted splicing in the variant protein ( Figure 3 ).
| DISCUSSION
Point mutations are the most common cause of hereditary disease. Most of them (84% in the HGMD) have been considered to change a single aminoacid (missense) or generate a premature stop codon (nonsense). 17, 18 However, in most cases mutation analyses are exclusively performed at the genomic DNA level, and the effect of a mutation on the encoded mRNA and protein is predicted from the primary sequence alone. Only few studies have evaluated experimentally the consequences of the mutation identified in a patient, and interestingly, about 50% of the mutations result in aberrant splicing. 19, 20 Actually, there is increasing evidence that many human disease genes are caused by mutations (also located at exons) that affect pre-mRNA splicing. 8, 9 Additionally, it is important to remark that the deleterious consequences of a mutation causing an aberrant splicing will potentially be higher than those from a missense mutation. Mutations affecting splicing sites, donor or acceptor, have obvious consequences on splicing. However, also nonsense, missense, and even synonymous muta- in the polypeptide chain. 15 However, in contrast to original proposition that the mutant allele is not expressed at the protein level 15 our study demonstrates that this variant is expressed and forms disulphide dimers by disturbing the correct folding of this serpin, like other missense mutations. 11 This is the first evidence that an aberrant splicing may also cause a type II antithrombin deficiency.
In conclusion, our study shows new evidences supporting that splicing mutations may play a more important role than previously thought in human hereditary disease. Aberrant splicing underlies a high proportion of cases with antithrombin deficiency, at least twice than the numbers proposed nowadays. Our study also confirms that the distortion of the correct splicing might be the mechanism involved in antithrombin deficiency caused by different types of gene defects. In addition to classical splicing site variations, deep intronic mutations and other gene variations including gross gene defects may cause antithrombin deficiency through an aberrant splicing. Missense and nonsense mutations in SERPINC1 might also disturb a correct splicing, as suggested by a recent study. 9 This large in silico study revealed that 21 out of 22 nonsense and 2 missense SERPINC1 mutations described in databases have high probability to affect the splicing. 9 Interestingly, one of these mutations, CM070261 p.(Lys157Arg) was identified in a patient from our cohort (P17) who had a type I deficiency (Table 1 ) despite this mutation affects a residue involved in the binding of heparin. 24 Therefore, it is possible that the number of mutations associated with aberrant splicing could be even higher than that suggested in this study, and it may increase if considering other regulatory elements involved in the splicing process. However, it is important to point out the requirement of further studies to verify the aberrant splicing suggested for mutations described in SERPINC1, which may include recombinant models, analysis of SERPINC1 transcripts and minigene models. Finally, our study shows that the consequences of an aberrant splicing are not restricted to the absence of protein encoded from the affected allele. As demonstrated in this study, an aberrant splicing in SERPINC1 may cause type I, type II or even moderate deficiency. As a final consideration; the elucidation of the pathological mechanism associated to one mutation is not only important from a basic point of view. It is also relevant for establishing the most appropriate and personalized therapeutic strategy at the molecular level, particularly with the promising results obtained to rescue mutations causing aberrant splicing.
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